KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Emergent BioSolutions (EBS) Amortization - Intangibles (2018 - 2026)

Emergent BioSolutions has reported Amortization - Intangibles over the past 9 years, most recently at $16.5 million for Q1 2026.

  • For Q1 2026, Amortization - Intangibles rose 1.23% year-over-year to $16.5 million; the TTM value through Mar 2026 reached $65.3 million, changed 0.15%, while the annual FY2025 figure was $65.1 million, 0.0% changed from the prior year.
  • Amortization - Intangibles for Q1 2026 was $16.5 million at Emergent BioSolutions, up from $16.3 million in the prior quarter.
  • Over five years, Amortization - Intangibles peaked at $17.9 million in Q4 2022 and troughed at $14.0 million in Q1 2022.
  • A 5-year average of $16.0 million and a median of $16.3 million in 2023 define the central range for Amortization - Intangibles.
  • Biggest five-year swings in Amortization - Intangibles: increased 27.86% in 2022 and later dropped 9.5% in 2023.
  • Year by year, Amortization - Intangibles stood at $17.9 million in 2022, then decreased by 9.5% to $16.2 million in 2023, then increased by 0.62% to $16.3 million in 2024, then grew by 0.0% to $16.3 million in 2025, then rose by 1.23% to $16.5 million in 2026.
  • Business Quant data shows Amortization - Intangibles for EBS at $16.5 million in Q1 2026, $16.3 million in Q4 2025, and $16.3 million in Q3 2025.